Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
Information source: Oslo University Hospital
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Thromboembolism; Acute Lymphoblastic Leukemia
Phase: N/A
Status: Recruiting
Sponsored by: Oslo University Hospital Official(s) and/or principal investigator(s): Ellen Ruud, MD PhD, Principal Investigator, Affiliation: Oslo University Hospital
Overall contact: Ellen Ruud, MD PhD, Phone: +47 23074560, Email: ellen.ruud@rikshospitalet.no
Summary
The study will examine the prevalence of venous thromboembolism in children with acute
lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008. The investigators will
prospectively study clinical symptomatic thromboses, asymptomatic central line-associated
thromboses, and infections.
Clinical Details
Official title: Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Clinical evident thrombosisAsymptomatic central line-associated thrombosis
Secondary outcome: Positive blood culture
Eligibility
Minimum age: 1 Year.
Maximum age: 16 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Acute lymphoblastic leukaemia,
- Age 1 year to 16 years old,
- Central line,
- Protocol NOPHO ALL 2008.
Exclusion Criteria:
- Refusal of participation,
- Treated according to protocol other than NOPHO ALL 2008.
Locations and Contacts
Ellen Ruud, MD PhD, Phone: +47 23074560, Email: ellen.ruud@rikshospitalet.no
Rikshospitalet, Dep of Pediatrics, Oslo 0027, Norway; Recruiting Ellen Ruud, MD PhD, Principal Investigator
Additional Information
The home page for NOPHO who is responsible for the ALL treatment protocol
Starting date: September 2009
Last updated: September 11, 2012
|